Search

Search Constraints

You searched for: Author/Creator Luciano, Luigiana

Search Results

1. Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis. (17th April 2019)

2. Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. Issue 10 (October 2015)

3. Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real‐life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. Issue 3 (17th April 2019)

4. Bosutinib in the real‐life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine‐kinase inhibitors. Issue 3 (13th March 2021)

5. Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second‐generation tyrosine kinase inhibitors in the real‐life practice: Identification of risk factors and the role of prophylaxis. Issue 7 (28th April 2018)

6. COVID‐19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. (11th October 2021)

7. Dasatinib first-line: Multicentric Italian experience outside clinical trials. (January 2016)

8. Erythropoietin treatment in chronic phase chronic myeloid leukemia patients treated with frontline imatinib who developed late anemia. (22nd May 2020)

9. Favorable outcome of chronic myeloid leukemia co‐expressing e13a2 and e14a2 transcripts, treated with nilotinib. Issue 4 (23rd July 2020)

10. Flow Cytometry Assessment of CD26+ Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia. Issue 4 (3rd February 2019)